New pill shows promise for Tough-to-Treat breast cancer
Disease control
Completed
This study tested a new hormone therapy pill, elacestrant, against standard treatments for people with a common type of advanced breast cancer (ER+/HER2-). The trial included 478 men and women whose cancer had worsened after previous hormone therapy. The goal was to see if elaces…
Phase: PHASE3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:01 UTC